1318: Immunocytochemical Distribution of Nitric Oxide Synthases in the Human Prostate

Richter, Karin; Heuer, Olaf; Ueckert, S.; Stief, Christian G.; Jonas, Udo; Wolf, Gerald

doi:10.1016/s0022-5347(18)38543-4

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nitric oxide synthase (NOS) is found in the normal prostate in two isoforms: endothelial NOS in the endothelial cells and under the form of neuronal NOS not only in nerve fibers transversing the fibromuscular prostatic stroma, but also, interestingly, in the cytoplasm of the basal cells. 14,15 It has been reported that NOS expression, and thus NO production, of the prostate is reduced in the transition zone of the prostate in benign prostatic hyperplasia (BPH), compared with normal prostate tissue. 16 The proposed reduction in expression of NOS isoforms results in increased smooth muscle cell contractile forces at the bladder neck and prostatic urethra.…”

Section: Luts and Ed: Pathophysiological Correlationsmentioning

confidence: 99%

Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management

2011

View full text Add to dashboard Cite

There is strong evidence from multiple epidemological studies that lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are correlated, independent of age or comorbidities as diabetes or hypertension. Although a direct causal relationship is not established yet, four pathophysio logical mechanisms can explain the relationship. These include alteration in nitric oxide bioavailability, a1-adrenergic receptor hyperactivity, pelvic atherosclerosis and sex hormones. This association has different clinical implications on the management of both disorders. Men seeking care for one condition should always be screened for complaints of the other condition. Sexual function should be assessed and discussed with the patient when choosing the appropriate management strategy for LUTS, as well as when evaluating the patient's response to treatment. Multiple large clinical trials have shown an improvement in LUTS after phosphodiesterase-5 (PDE5)-inhibitor treatment. PDE5 inhibitors show promise as a future treatment for LUTS, either in conjunction with existing therapies or as a primary treatment. There may be a potential therapeutic role for testosterone in LUTS treatment in cases of testosterone deficiency that needs to be investigated. Much further investigation is required, but it is evident that the association between LUTS and ED is fundamental for future therapies and possible preventative strategies.

show abstract

Section: Luts and Ed: Pathophysiological Correlationsmentioning

confidence: 99%

Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management

2011

View full text Add to dashboard Cite

show abstract

“…NOS is found in the normal prostate in two isoforms: endothelial NOS (eNOS) in the endothelial cells and under the form of neuronal NOS (nNOS) not only in nerve fibers transversing the fibromuscular prostatic stroma, but also, interestingly, in the cytoplasm of the basal cells. 18,19 It has been reported that NOS expression, and thus NO production, of the prostate is reduced in the transition zone of the prostate in BPH, compared with normal prostate tissue. 20 The proposed reduction in expression of NOS isoforms resulted in increased smooth muscle cell contractile forces at the bladder neck and prostatic urethra.…”

Section: Alteration In No Levelsmentioning

confidence: 99%

Role of Phosphodiesterase Type 5 Inhibitor on Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

Kim

Park

2011

Korean J Androl

View full text Add to dashboard Cite

= Abstract =There is strong evidence from multiple epidemiological studies that benign prostate hyperplasia (BPH) induced lower urinary tract symptoms (LUTS) are correlated with erectile dysfunction (ED). Although a direct causal relationship is not established yet, four pathophysiological mechanisms can explain the relationship. These include alteration in and LUTS in subjects with ED. Basically PDE5 I with long half life is an appropriate candidate, therefore tadalafil and undenafil had been used to evaluate both diseases. Placebo-controlled trials of tadalafil showed improvement of LUTS secondary to BPH, but none of the studies showed a significant effect on urodynamic measures. PDE5 Is, such as sildenafil and tadalafil, increase the concentration of cGMP in plasma and smooth muscle, facilitating erection of the penis, relaxation of the bladder neck and prostate and subsequent bladder emptying. And theses PDE5 Is increase cAMP and cGMP levels and are more highly distributed in the prostate than plasma. These findings may help in the assessment of the feasibility of using PDE5 Is to concurrently treat both LUTS and ED.

show abstract

“…Burnett et al 21 have shown the presence of neurogenic NOS in nerve tissue in the prostate's transition zone. Studies by Richter et al 22 and Bloch et al 23 detected endothelial NOS in the vascular supply of the prostate and neurogenic NOS in the nerve fibers of the fibromuscular stroma, respectively. Gradini et al 24 through immunohistochemical and polymerase chain reaction analysis showed expression of endothelial NOS in normal and hyperplastic prostatic tissue, whereas neurogenic NOS was prevalent in the secretory layer of glandular epithelium.…”

Section: Nos/no Theorymentioning

confidence: 97%

PDE5 inhibitors for LUTS

Mouli

McVary

2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

To review the current literature regarding the relationship between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED), and the role of phosphodiesterase-5 (PDE5) inhibitors for the treatment of LUTS. Review of recently published (1990)(1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009) Keywords: erectile dysfunction; benign prostatic hyperplasia; lower urinary tract symptoms; LUTS; ED IntroductionLower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are highly prevalent in aging males, with a substantial impact on quality of life (QOL). Multiple studies have shown a strong association between these two entities, independent of other risk factors. This relationship may be explained by four interrelated theories: the nitric oxide/cyclic guanosine monophosphate pathway (NO/cGMP), the Rho-kinase pathway, autonomic hyperactivity (AH), and pelvic atherosclerosis. Clinical trials have shown that phosphodiesterase-5 (PDE5)-inhibitor treatment results in significant improvement in LUTS. The exact mechanism of action is not well understood. The results of these studies indicate that PDE5-inhibitor treatment has a role in treating LUTS in the setting of ED. Furthermore, PDE5-inhibitor therapy may expand to treat not only men with ED and/or LUTS, but also LUTS in women.

show abstract

1318: Immunocytochemical Distribution of Nitric Oxide Synthases in the Human Prostate

Cited by 6 publications

References 0 publications

Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management

Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management

Role of Phosphodiesterase Type 5 Inhibitor on Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

PDE5 inhibitors for LUTS

Contact Info

Product

Resources

About